Apellis Pharmaceuticals, Inc. (APLS) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Apellis Pharmaceuticals, Inc. (APLS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $5.25B, listed on NASDAQ, employing roughly 705 people, carrying a beta of -0.25 to the broader market. Apellis Pharmaceuticals, Inc. Led by Cedric Francois, public since 2017-11-09.
Snapshot as of May 22, 2026.
- Spot Price
- $39.17
- Max Pain Strike
- $40.00
- Total OI
- 27.8K
As of May 22, 2026, Apellis Pharmaceuticals, Inc. (APLS) max pain sits at $40.00, which is above the current spot price of $39.17 (2.1% away). Spot sits 2.1% above max pain - close enough that a routine end-of-cycle gamma roll could pull price toward the level, but far enough that catalyst-driven flow would dominate. APLS sits in the lower-price band (spot $39.17), where $0.50-$2.50 strike spacing makes pin-to-strike effects easy to spot but per-contract dollar gamma is smaller. Total open interest across the listed chain is comparatively thin (27.8K contracts), so single-strike pinning is less reliable than it is for high-OI names. APLS is currently in positive dealer gamma ($705.6K), the regime that mechanically reinforces pinning by inducing dealers to buy weakness and sell strength near heavy-OI strikes. Max pain identifies the strike at which the aggregate dollar value of all outstanding options contracts would expire with the least total intrinsic value, a gravitational reference rather than a price target.
APLS Strategy Implications at the Current Max Pain Level
With spot 2.1% from the $40.00 max-pain level and Apellis Pharmaceuticals, Inc. in a positive-gamma regime, where dealer hedging mechanically pulls spot toward heavy-OI strikes, strategy selection turns on cycle position and dealer positioning. Iron condors and credit spreads centered near the max-pain strike capture the typical end-of-cycle convergence when the regime supports pinning; ratio backspreads or directional debit structures fit names where catalyst flow is likely to overwhelm the hedging-driven pull. The gamma-exposure page shows the per-strike dealer book that determines whether hedging will reinforce or fight the pin.
How to read the APLS max-pain chart
The open-interest histogram above shows where Apellis Pharmaceuticals, Inc. call and put writers have stacked the most inventory. Strikes with elevated call OI act as overhead resistance when dealers are long-gamma (they sell rallies into the wall); strikes with elevated put OI act as support (dealers buy dips toward the wall). The max-pain strike is the single price at which the total cash payout to option holders is minimized - the lowest-pain price for the writers as a group. The max-pain strike sits at $40.00, 2.1% above spot. Net dealer gamma is positive at $705.6K, so as spot moves dealers sell rallies and buy dips, mechanically dampening realized volatility.
APLS max-pain in context
Max pain is an end-of-cycle convergence signal, not an intraday compass. Cross-reference the level with the gamma-flip strike on the GEX page, the front-month ATM IV reading (currently 25.3%), and any catalyst risk on the calendar. Total listed OI on APLS sits at 27.8K contracts; pin strength generally scales with this number, since heavier OI means more delta to hedge as spot drifts toward the strike. A pin can fail - earnings, FDA decisions, central-bank surprises, and other vol catalysts can rip spot past max pain regardless of where dealers want it. Use max pain to size risk-defined structures, not as a directional thesis.
Reading APLS max-pain alongside dealer positioning
The clean version of the max-pain mechanism requires positive dealer gamma to enforce convergence; in a negative-gamma regime the same OI distribution can repel rather than attract spot. APLS is currently in a positive-gamma regime, so the max-pain pull mechanic is structurally active. Combine the pin level with the gamma-flip level and the implied move to model out where spot is likely to anchor through expiration.